Not Yet RecruitingNot Applicable

Endoscopic Resection for Small Rectal Neuroendocrine Tumors

120 participantsStarted 2025-03

Plain-language summary

According to clinical practice and relevant retrospective research data, both modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic mucosal resection with a ligation device(ESMR-L) were reported to be effective for the treatment of small rectal neuroendocrine tumors (NETs) . However, there is a lack of multicenter prospective studies to evaluate the advantages and disadvantages of mEMR-C and mEMR-L. mEMR-C is the modified ESMR-L without submucosal injection.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age from 18 to 80 years;
✓. With a high suspicion or evidence of rectal NET assessed using EUS or colonoscopy;
✓. With tumor size ≤10 mm assessed by colonoscopy;
✓. Plan to receive mEMR-C or mEMR-L treatment and provide written informed consent;

Exclusion criteria

✕. Unable to tolerate mEMR-L or mEMR-C as assessed by the research team of each center;
✕. Complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation;
✕. Rectal NET with lymph node metastasis or distant metastasis;
✕. Received resection of rectal neuroendocrine tumor by other surgical procedures;
✕. Multiple rectal neuroendocrine tumors;
✕. Vulnerable groups such as pregnant women or patients with mental disorders;
✕. Poor compliance, unable to cooperate with treatment.

What they're measuring

histological complete resection

Timeframe: within 14 days after procedure

Trial details

NCT IDNCT06901856

SponsorGuangdong Provincial People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

View on ClinicalTrials.gov More Rectal Neuroendocrine Tumor trials